Inovio reports interim Phase I data for HBV candidate

Inovio Pharmaceuticals Inc. (NASDAQ:INO) reported interim data from a Phase I trial showing that HBV candidate INO-1800

Read the full 171 word article

How to gain access

Continue reading with a
two-week free trial.